Hongling Peng

17PUBLICATIONS
30CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)Tumour immunologyHaematological tumoursHaematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Jul 05, 2026
Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.

|Jun 23, 2026
Venetoclax combined with intensive chemotherapy as induction chemotherapy in newly diagnosed AML with FLT3-ITD-mutation.

|Jan 12, 2026
HLTF cooperates with GATA1 to activate transcriptional programs and chromatin remodeling during erythroid development.

Han Gong, Bin Hu, Ling Nie

|Nov 22, 2025
Clinical characteristics and survival outcomes of thymic mucosa-associated lymphoid tissue lymphoma: A multicenter analysis of 82 patients.

Wenyu Shi, Yimin Ren, Shu Liu

|Oct 28, 2025
Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study.

Yaxian Tan, Xingli Zhao, Xiaohui Suo

|Apr 29, 2025
Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma.

Lixia Sheng, Hailing Liu, Xiaohui Zhang

Pageof 3

Frequent Collaborators

3 joint publications

Heng Li

3 joint publications

Jing Liu

2 joint publications

Yingchang Mi

2 joint publications

Kaiqi Liu